#medullary thyroid cancer

[tockamybeloved]

[atassociation12]

https://www.thyroid.org/

The American Thyroid Association® (ATA) is the professional home for clinicians and researchers dedicated to thyroid health. Learn more and join us.

[myhealingera]

Two weeks after this photo was taken, I received a phone call that nobody ever wants to receive.

I was dealing with a slew of health issues: an inability to lose weight, hair loss, swollen lymph nodes, fatigue so intense that getting out of bed felt like a miracle, and severe brain fog. My joints were in so much pain that I found myself using a heating pad for most of the day.

I consulted my aunt, who is a pediatrician, and she reviewed my recent blood work. She observed that my TSH levels were consistently borderline high, often surpassing the normal threshold. Encouraged by her insight, I visited my OBGYN and shared my symptoms. She ordered hormone testing and referred me to a rheumatologist, given that lupus runs in my family. The results indicated elevated TSH, DHEA, and C-reactive protein levels.

I then saw a remarkable rheumatologist who conducted over 120 tests. All came back normal except for my thyroid antibodies, and I was diagnosed with arthritis in my hands. Around this time, my neck began to swell, feeling as though something was stuck in my throat. My primary care physician scheduled an ultrasound, which revealed swelling in my neck and a lymph node, and identified a nodule or "ectopic" tissue.

Returning to my primary care doctor, I was told my lab results were normal and advised to follow up in a year, despite continuing to experience swollen lymph nodes and being told that the neck nodule was unrelated to the swelling. At this point had been to urgent care 3 times, completed 3 rounds of steroids, a z-pack, and tested negative for mono, Covid, and strep.

Despite my tendency to avoid conflict, something felt off, and I knew I wasn't okay.

I requested a referral to an endocrinologist, which I received, but they couldn't see me until after Christmas. Not wanting to wait, I found another endocrinologist who could see me on Halloween. At my first appointment, I was diagnosed with Hashimoto’s thyroiditis and hypothyroidism. She ordered a biopsy "to be safe," emphasizing that a finding warrants investigation. Even at the hospital for my biopsy, the PA questioned its necessity given my primary care's advice to wait a year.

On 12/22, my endocrinologist informed me that the biopsy results were suspicious for thyroid carcinoma. I returned on 1/5 to discuss the findings.

They had sent my sample for Afirma testing, a genetic test for medullary thyroid cancer, due to the unusual results and the aggressive nature of the potential cancer.

I was then referred to an ENT, who suspected the nodule might actually be a lymph node. A CT scan confirmed this suspicion, revealing a lymph node suspicious for thyroid cancer, yet with no nodules on my thyroid itself.

The decision was made to remove the lymph node, with intraoperative pathology consultation to decide whether to also remove the thyroid.

On 2/24, the lymph node was removed, but pathology was indeterminate, leading to the decision not to remove the thyroid.

The following week, I was informed that my results had been sent to a larger university hospital for further analysis and a second opinion, an ominous sign according to my ENT.

Ultimately, it was confirmed as papillary thyroid cancer that had begun to metastasize to the lymph nodes, indicating occult thyroid cancer, typically undetected until it spreads to the lymph nodes. Likely, there are microcarcinomas on my thyroid undetectable by imaging. Thus, another surgery is required.

My complete thyroidectomy is scheduled for 4/24.

Honestly, none of this truly sank in until I received a call from the hospital's oncology department to schedule a radiation consultation for post-surgery RAI treatment.

It’s been an incredibly tough start to the year, to say the least.

[arrangoiz]

Effect of Primary Tumor Resection on Survival Outcomes for Stage IV Medullary Thyroid Carcinoma

Article: Liu C-Q, Shen C-K, Du Y-X, et al. Survival outcome and optimal candidates of primary tumor resection for patients with metastatic medullary thyroid cancer. J Clin Endocrinol Metab 2024;109(11):2979-2985; doi: 10.1210/clinem/dgae214. PMID: 38570918. Background: Medullary thyroid cancer (MTC): Is a rare malignancy with high metastatic potential Distant metastases are present in 10% of…

[iebpharma1]

Tizaro(Tirzepatide) 2.5mg/ 5mg/ 7.5mg Medicine

Tirzepatide, marketed under the brand name Tizaro, is a cutting-edge medication used primarily for the management of type 2 diabetes and weight loss. It comes in three strengths: 2.5 mg, 5 mg, and 7.5 mg, each designed to address the diverse needs of patients. Tizaro is classified as a dual GLP-1 (glucagon-like peptide-1) receptor agonist and GIP (gastric inhibitory peptide) receptor agonist, offering a novel approach to managing blood sugar levels and promoting weight loss.

Mechanism of Action

Tizaro works by mimicking the action of two natural hormones in the body—GLP-1 and GIP. GLP-1 is a hormone involved in the regulation of blood sugar, appetite, and insulin secretion. By activating GLP-1 receptors, Tizaro(Tirzepatide) 2.5mg/ 5mg/ 7.5mg helps to stimulate insulin release in response to meals and inhibits glucagon secretion, which helps lower blood sugar levels. Additionally, Tizaro slows down gastric emptying, making individuals feel fuller longer and contributing to weight loss.

GIP, another key hormone in Tizaro's mechanism, works synergistically with GLP-1. By stimulating the GIP receptors, the medication enhances the effects of insulin in the body, further promoting better blood sugar control. This dual action of Tizaro on both GLP-1 and GIP receptors sets it apart from other diabetes treatments, providing superior efficacy in managing blood glucose and weight in patients with type 2 diabetes.

Indications and Uses

Tizaro is approved for use in patients with type 2 diabetes to improve blood sugar control. It is often prescribed when lifestyle modifications, such as diet and exercise, have not been sufficient in achieving adequate blood sugar control. In addition to its role in managing diabetes, Tizaro has also been found to aid in weight loss, making it an attractive option for overweight or obese individuals with type 2 diabetes. The weight loss benefits are an important consideration for healthcare providers, as excess weight is a major risk factor in the progression of type 2 diabetes.

Dosage and Administration

Tizaro is available in three strengths: 2.5 mg, 5 mg, and 7.5 mg. The medication is administered via subcutaneous injection, typically once a week, in the abdominal area or thigh. The starting dose is usually 2.5 mg, and the dose can be increased every four weeks, based on the patient's tolerance and response to the medication. The goal is to find the optimal dose that effectively controls blood sugar and promotes weight loss, without causing intolerable side effects.

Side Effects and Safety

Like all medications, Tizaro may cause side effects, although not everyone will experience them. The most common side effects include nausea, diarrhea, and reduced appetite. These side effects typically occur during the first few weeks of treatment and may subside as the body adjusts to the medication. However, in some cases, they can persist. Patients may also experience headache, fatigue, and dizziness.

In rare instances, Tizaro may cause more serious side effects, such as pancreatitis or kidney problems. It is essential for patients to discuss their medical history with their healthcare provider before starting treatment, especially if they have a history of pancreatitis, kidney disease, or other serious conditions. Tizaro should not be used in individuals with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2.

Conclusion

Tizaro (Tirzepatide) is a breakthrough medication for individuals with type 2 diabetes, offering effective blood sugar control and significant weight loss benefits. Available in doses of 2.5 mg, 5 mg, and 7.5 mg, it provides flexibility in treatment and can be tailored to meet the individual needs of patients. By activating both GLP-1 and GIP receptors, Tizaro provides a dual mechanism of action that sets it apart from traditional diabetes medications, making it a valuable addition to the treatment options available for those managing type 2 diabetes. As with all medications, it is important to follow the prescribed dosing regimen and discuss any potential side effects with a healthcare provider to ensure the best outcomes.

[thyroidsurgeryuae-blog]

Thyroid Cancer in the UAE: Understanding Risk Factors, Symptoms, Diagnosis, and Treatment Options

Thyroid cancer is one of the most common endocrine malignancies affecting individuals worldwide, including the UAE. With advancements in medical technology and awareness, early detection and effective treatment options have significantly improved patient outcomes. This blog explores the key aspects of Thyroid Cancer in the UAE, including its risk factors, symptoms, diagnosis, and treatment options.

Understanding Thyroid Cancer

The thyroid gland, located at the base of the neck, plays a crucial role in regulating metabolism through hormone production. Thyroid cancer occurs when abnormal cells grow uncontrollably in this gland. It is generally categorized into different types, including papillary, follicular, medullary, and anaplastic thyroid cancer.

Risk Factors for Thyroid Cancer in the UAE

Several factors contribute to the likelihood of developing thyroid cancer, including:

Genetic predisposition: A family history of thyroid cancer increases the risk.

Radiation exposure: Previous exposure to radiation therapy, especially in the head or neck area.

Iodine deficiency: A lack of iodine in the diet can lead to thyroid abnormalities.

Gender and age: Women are more likely to develop thyroid cancer, particularly between the ages of 30 and 50.

Environmental factors: Lifestyle habits and environmental pollution may play a role in thyroid disorders in regions like Thyroid Cancer Dubai and Thyroid Cancer Abu Dhabi.

Common Symptoms of Thyroid Cancer

Thyroid cancer often does not present noticeable symptoms in its early stages. However, as it progresses, individuals may experience:

A lump or swelling in the neck

Hoarseness or changes in voice

Difficulty swallowing or breathing

Persistent cough unrelated to colds

Pain in the neck or throat

Diagnosis of Thyroid Cancer

Early detection plays a crucial role in effective treatment. Diagnosis typically involves:

Physical Examination: A doctor checks for lumps or abnormalities in the thyroid.

Ultrasound Imaging: Helps determine the nature of thyroid nodules.

Fine Needle Aspiration Biopsy (FNAB): A sample is taken from the thyroid for testing.

Blood Tests: Assess thyroid function and detect any irregularities.

CT or MRI Scans: Used for advanced evaluation in some cases.

Treatment Options for Thyroid Cancer

Treatment plans depend on the type and stage of thyroid cancer. Common options include:

Surgery: The primary treatment for thyroid cancer, involving partial or total thyroid removal.

Radioactive Iodine Therapy: Used to destroy remaining thyroid cells after surgery.

Hormone Therapy: Helps maintain normal metabolism and prevent cancer recurrence.

External Radiation Therapy: Used for aggressive thyroid cancer cases.

Targeted Drug Therapy: Advanced treatment for specific types of thyroid cancer.

Conclusion

Thyroid cancer, though concerning, is treatable with early detection and proper medical care. If you experience any symptoms or have risk factors, consult a specialist for timely diagnosis and intervention. For more details on thyroid cancer management in the UAE, visit Thyroid Cancer UAE.

Raising awareness and seeking medical guidance can make a significant difference in improving thyroid cancer outcomes. Stay informed and take proactive steps toward thyroid health.

[retevmocapsule]

All About Retevmo capsules

Globally, Selpercatinib is supplied under the brand Retevmo. It is a drug that has been approved by the FDA to treat certain types of advanced cancer. It is mostly used in the case of patients with cancer who have particular gene mutations or rearrangements with Non-Small Cell Lung Cancer (NSCLC), Medullary Thyroid Cancer (MTC), and Thyroid Cancer. However, Retevmo price in India can vary as it has not been approved in the country and has to be bought via legal import channels.

Uses of Retevmo:

Retevmo (Selpercatinib) works like certain other drugs, compounds that inhibit cancerous cells, in this instance specifically proteins that are RET fusion-positive. This form of targeted therapy helps the management of aggressive humor growth as well as effectively managing symptoms. The medicine is used for the treatment of:

adults with RET Fusion Positive NSCLC

MTC Mutant Medullary Children aged 12 years and older having Children and Advanced or Metastatic RET-P

patients aged 12 years or older with RET fusion-positive thyroid cancer that is advanced or metastatic and does not respond to iodine radio treatment.

How to Access Retevmo in India?

Formally, Retevmo is what is referred to as a ‘not yet approved’ medicine in India still it can be obtained through a Named Patient Import Permit which is a legal framework. Indian patients who are in constant need of this medicine can coordinate with reputable facilitators who import this medicine from reliable sources all over the globe.

Side Effects Of Retevmo:

All therapeutic drugs have their side effects, and Selpercatinib is not an exception. Some of the side effects include:

increase in liver enzyme levels

loose motions

xerostomia

arterial hypertension

edema of the hands and feet

tiredness

Other side effects that are serious but rare include QT prolongation (which is a heart rhythm disorder) and liver damage (hepatotoxicity) but regular monitoring from a professional is needed when on the medication.

Dosage And Availability: Retevmo comes in two dosage strengths which are 40 mg and 80 mg oral capsules. The capsules are taken in doses determined by the physician after taking into account the weight and treatment of the patient.

Why Choose Us To Access Retevmo?

We, Indian patients who wish to look for Selpercatinib (Retevmo) help them from the start till the end with the process of seeking to import it, and this way they avoid the legal issues concerning such matters. With our years of experience, we ensure that this medicine is procured legally and is also reliable for the patients. Our team works with licensed global suppliers to meet quality, authenticity, and timely delivery.

In case you want to buy Retevmo 40 mg/80 mg online in India, kindly reach out to us via Call/WhatsApp: +91 9310090915 or TOLL-FREE Number: 1800-889-1064. We will provide you with professional help with the whole process. 

What is Retevmo and how can I access it in India?

Retevmo (Selpercatinib) is an advanced cancer treatment targeting RET fusion-positive cancers. As it is not yet approved in India, it can only be accessed through a legal Named Patient Import Permit. Indian Pharma Network (IPN) facilitates its import for eligible patients.

Can I buy Retevmo 40 mg/80 mg online?

Yes, you can buy Retevmo 40 mg and 80 mg online in India through licensed suppliers who facilitate its legal import. Indian Pharma Network ensures patients receive genuine Retevmo capsules from reliable global sources, providing a seamless and secure process.

Is Retevmo 40 mg/80 mg approved in India?

No, Retevmo (Selpercatinib 40 mg/80 mg) has not yet been approved by Indian regulatory authorities. Patients requiring the medicine must apply for a Named Patient Import Permit to access it legally from international suppliers.

Where can I buy Retevmo in Lucknow, Delhi, Noida, and other cities?

You can buy Retevmo in Lucknow, Delhi, Noida, and across India through the Indian Pharma Network (IPN). IPN can assist patients nationwide and ensure the legal and timely import of Retevmo for those in need.

How can the Indian Pharma Network (IPN) help in importing Retevmo 40 mg/80 mg?

Indian Pharma Network (IPN) facilitates the legal import of Retevmo capsules by assisting patients with documentation. We connect with licensed global suppliers, and ensuring genuine and timely delivery to meet urgent medical needs.

[fitnesscoachs-blog]

WHAT TO KNOW ABOUT WEGOVY 1.0MG PREFILLED PEN

Wegovy 1.0mg contains semaglutide, a GLP-1 receptor agonist that:

– Regulates appetite and metabolism

– Enhances insulin sensitivity

– Supports significant and sustainable weight loss

Clinically Proven, Expert-Endorsed

Wegovy 1mg has been extensively studied in clinical trials, demonstrating:

– Average weight loss of 15-20% body weight

– Improved glycemic control and cardiovascular outcomes

– Well-tolerated with minimal side effects

Maximum Weight Loss, Minimal Effort

Wegovy 1mg offers:

– Convenient once-weekly injection

– Flexible dosing schedule

– Easy-to-use pen device

Why Wegovy 1.0mg Stands Alone

– Highest available dose for maximum efficacy

– Targeted approach to weight loss and metabolic control

– Potential for long-term weight management and overall health improvement

Maximize Your Weight Loss Results

Don’t settle for mediocre weight loss results. Choose Wegovy 1mg and discover a more effective, sustainable solution. Consult your healthcare provider today and unlock your full weight loss potential.

Before taking wegovy 1.0mg

You should not use this medicine if you are allergic to it or if you have:

multiple endocrine neoplasia type 2 (tumors in your glands);

a personal or family history of medullary thyroid carcinoma (a type of thyroid cancer); or diabetic ketoacidosis (call your doctor for treatment).

Tell your doctor if you have ever had:

a stomach or intestinal disorder;

pancreatitis;

kidney disease;

eye problems caused by diabetes (diabetic retinopathy)

[tockamybeloved]

Another year as a Meddie survivor! Medullary Thyroid Cancer | ThyCa: Thyroid Cancer Survivors' Association, Inc.

[impomed]

Selpercatinib 40 & 80 mg in India is a cutting-edge anticancer medication used for treating RET fusion-positive non-small cell lung cancer (NSCLC) and thyroid cancer, including medullary thyroid carcinoma. Available through Impomed Healthcare, this targeted therapy blocks the RET kinase enzyme, slowing cancer cell growth. With its targeted action, flexibility in dosage, and fewer side effects, Selpercatinib 40 & 80 mg in India offers hope and improved survival for cancer patients across the country.

For more information click on this link-:https://www.impomedhealthcare.com

[oncologistseemasingh]

Learn about the different types of thyroid cancer, including papillary, follicular, medullary, and anaplastic. Explore this comprehensive guide to gain insights into the diverse nature of thyroid cancer.

[drcare4u]

FDA Approves Retevmo for Some With Medullary Thyroid Cancer

The FDA has approved Retevmo for select pediatric and adult patients with medullary thyroid cancer who have RET mutations. The Food and Drug Administration (FDA) approved Retevmo (selpercatinib) for the treatment of adults and children aged 2 years and older with advanced or metastatic medullary thyroid cancer with a RET mutation who require systemic therapy. According to the alert from the FDA,…

[twinkl22004]

“Medullary Thyroid Carcinoma”, Victor McKusick, Mendelian Inheritance in Man, 1966.

Here I present: “Medullary Thyroid Carcinoma”, Victor McKusick, Mendelian Inheritance in Man’, 1966. INTRODUCTION. Medullary thyroid carcinoma (MTC) is a form of thyroid carcinoma which originates from the parafollicular cells (C cells), which produce the hormone calcitonin.   MTC was first characterized in 1959; and, is the third most common of all thyroid cancers. There is evidence familial…

[arrangoiz]

Predicting Survival Outcomes: The Updated AJCC/TNM Staging System

In October 2016: The AJCC (www.cancerstaging.org) published the eighth edition of the AJCC / TNM cancer staging system: Which replaced the seventh edition that had been used by clinicians, cancer registries, and researchers since 2009 On January 1st, 2018: Tumor registries officially began using the eighth edition for tumor staging Whereas the staging tables for medullary thyroid cancer and…

[theindianpharma]

Cabozantinib, a tyrosine kinase inhibitor (TKI) is used for treating several types of cancer, including renal cell carcinoma (RCC), medullary thyroid cancer (MTC), and hepatocellular carcinoma (HCC).